Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

Rhea-AI Summary

Aspire Biopharma (NASDAQ:ASBP) closed the second and final tranche of a private placement, issuing an aggregate of 26,250 Series A convertible preferred shares for total gross proceeds of $21.0 million, before fees.

The company secured a commitment letter for a senior secured credit facility of up to $22.5 million to finance a proposed $30.0 million cash acquisition of Dura Control Systems (DCS), which reported $200M+ revenue and $20M adjusted EBITDA for FY2025 (unaudited). Aspire said stockholders' equity now exceeds the Nasdaq $2.5M listing minimum and that the DCS purchase is not expected to require new equity.

Positive

• Raised $21.0M from Series A preferred private placement
• Commitment letter for up to $22.5M senior secured credit facility
• LOI to acquire DCS for $30.0M cash
• DCS: $200M+ revenue and $20M adjusted EBITDA for FY2025
• Stockholders' equity now > $2.5M to maintain Nasdaq listing

Negative

• Aspire Credit Facility interest at +325 bps above one‑month SOFR
• Acquisition would add up to $22.5M senior secured debt
• Credit facility and acquisition are subject to definitive documentation and customary closing conditions

News Market Reaction – ASBP

-2.89% 64.8x vol

77 alerts

-2.89% Session close to close

+57.6% Peak Tracked

-43.4% Trough Tracked

$1.63M Market Cap

64.8x Rel. Volume

In the Apr 20 session, ASBP declined 2.89%, reflecting a moderate negative market reaction. Argus tracked a peak move of +57.6% during that session. Argus tracked a trough of -43.4% from its starting point during tracking. Our momentum scanner triggered 77 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 64.8x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details completion of a $21M private placement and a commitment letter for a $22.5...

Analysis

This announcement details completion of a $21M private placement and a commitment letter for a $22.5M senior secured credit facility intended to fund a $30M cash acquisition of DCS, which reported $200M+ revenue and $20M+ Adjusted EBITDA in FY2025. Investors may track closing of definitive loan documents, final acquisition terms, and integration progress, alongside Aspire’s ability to balance leverage with its ongoing capital needs for the sublingual delivery and BUZZ BOMB™ businesses.

Key Figures

Private placement total: $21.0M Second tranche proceeds: $10.0M Preferred Shares issued: 12,500 shares +5 more

8 metrics

Private placement total $21.0M Aggregate gross proceeds from Series A Convertible Preferred Stock Offering

Second tranche proceeds $10.0M Gross proceeds from 12,500 Preferred Shares in final tranche

Preferred Shares issued 12,500 shares Series A Convertible Preferred Stock in second and final tranche

Total Preferred Shares 26,250 shares Total Series A Convertible Preferred Stock sold in Offering

Credit facility commitment $22.5M Senior secured credit facility to finance DCS acquisition

DCS purchase price $30M Cash consideration to acquire 100% of DCS, if consummated

DCS FY2025 revenue $200M+ Unaudited 2025 revenue for DCS

DCS FY2025 Adjusted EBITDA $20M+ Unaudited Adjusted EBITDA for DCS in FY2025

Historical Context

5 past events · Latest: Apr 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 16	Acquisition LOI	Positive	-44.9%	Announced LOI to acquire DCS for $30M cash with $200M+ 2025 revenue.
Apr 15	Retail partnership	Positive	-54.2%	Buzz Bomb partnered with Interwest Brokerage to expand BUZZ BOMB™ retail footprint.
Mar 19	Distribution deal	Positive	-6.0%	Buzz Bomb engaged TruLife Distribution to drive national retail expansion of BUZZ BOMB™.
Mar 17	Management hire	Positive	-10.2%	Appointed experienced sales director to scale Buzz Bomb’s western U.S. presence.
Mar 12	Product showcase	Positive	-10.0%	Planned BUZZ BOMB™ showcase at The Health & Fitness Show 2026 in San Diego.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive operational and acquisition headlines have repeatedly coincided with sharp negative price reactions, suggesting the market has been skeptical of ASBP’s growth and capital-raising plans.

Recent Company History

Over the past months, Aspire Biopharma has announced multiple growth initiatives, including BUZZ BOMB™ distribution partnerships and the $30M cash LOI to acquire DCS with $200M+ FY2025 revenue. Yet each update, including sales leadership hires and trade show exposure, was followed by double‑digit percentage declines (e.g., -54.21%, -44.94%). Today’s private placement completion and credit facility commitment fit this pattern of strategic expansion funded by external capital against a weak share price backdrop.

Key Terms

series a convertible preferred stock, adjusted EBITDA, letter of intent, senior secured credit facility, +3 more

7 terms

series a convertible preferred stock financial

"purchase and sale of 26,250 shares of Series A Convertible Preferred Stock."

Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.

adjusted EBITDA financial

"DCS delivered more than $20M in Adjusted EBITDA on $200M+ Revenue for FY2025"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

letter of intent financial

"it has entered into a Letter of Intent (LOI) to acquire DCS"

A letter of intent is a document that shows an agreement in principle between parties to work towards a future deal or transaction. It outlines their intentions and key terms, acting like a roadmap before a formal contract is signed. For investors, it signals serious interest and helps clarify expectations early in the process.

senior secured credit facility financial

"providing for a senior secured credit facility of Aspire in an aggregate principal amount"

A senior secured credit facility is a loan or revolving line of credit where lenders have first legal claim on specific company assets (collateral) and the debt ranks above other obligations for repayment. For investors it signals where a lender sits in the repayment pecking order and how much protection creditors have if the company struggles, affecting credit costs, the company’s ability to borrow more, and potential recoveries in a default — like a mortgage taking priority over other claims on a house.

term loan financial

"consist of a senior secured five-year term loan, at an interest rate equal to 325"

A term loan is a type of loan that is borrowed for a set period of time, with a fixed schedule for repaying the money, usually in regular payments. It matters to investors because it represents a company's borrowing costs and financial stability; reliable repayment of these loans can indicate strong financial health, while difficulties may signal potential risks.

secured overnight financing rate financial

"interest rate equal to 325 basis points above the one-month term Secured Overnight Financing Rate."

A secured overnight financing rate (SOFR) is a daily benchmark interest rate that reflects the cost of borrowing cash overnight using U.S. Treasury securities as collateral. Think of it as the market price to “rent” cash for a day with a very safe pledge, similar to paying a short-term rental fee for money backed by government bonds. Investors track SOFR because it underpins pricing for loans, bonds and derivatives, so movements change borrowing costs, interest income and the valuation of interest-rate–linked positions.

placement agent financial

"acted as sole placement agent for the private placement."

A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Company secures Commitment Letter from a leading financial institution of up to $22.5M to finance proposed acquisition of Dura Control Systems (DCS)

• LOI to acquire DCS, a leading global automotive supplier with $200M+ in 2025 revenue, is not expected to require new equity raise to consummate the purchase

ESTERO, FL / ACCESS Newswire / April 20, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company") today announced that it has closed the second and final tranche of the private placement announced on February 11, 2026 (the "Offering") for the purchase and sale of 26,250 shares of Series A Convertible Preferred Stock.

Pursuant to the closing of the second and final tranche of the Offering, the Company issued an aggregate of 12,500 Preferred Shares for gross proceeds of $10.0 million. With the completion of this tranche of the Offering, total aggregate gross proceeds to the Company were $21.0 million, before deducting placement agent fees and other offering expenses. Based on the total proceeds, the Company's stockholders' equity now exceeds the $2.5 million minimum required to maintain its listing on the Nasdaq Capital Market.

The Company intends to use the net proceeds from the transaction to support working capital, to fund a portion of the cash component of the proposed DCS acquisition, and other general corporate purposes.

Additional information regarding the Offering is available in the Company's Current Report on Form 8-K/A filed on April 17, 2026 with the SEC.

"Finalizing this $21 million raise is a transformative step for Aspire," said Kraig Higginson, Interim CEO. "These funds solidify our capital position as we advance our sublingual delivery platform and accelerate consumer awareness and retail expansion of BUZZ BOMB™, our innovative caffeine product. Simultaneously, we are executing a dual-track growth strategy, by pursuing a high-revenue, cash-flow-positive acquisition of DCS that, if consummated, could substantially enhance our financial position."

LOI to Acquire DCS

The Company announced on April 15, 2026 that it has entered into a Letter of Intent (LOI) to acquire DCS, a premier designer and manufacturer of automotive driver control systems that also apply to other industrial applications. DCS delivered more than $20M in Adjusted EBITDA on $200M+ Revenue for FY2025 (unaudited). Aspire is expected to acquire 100% of DCS for a total purchase price of $30million paid in cash.

Commenting on the Company's recently announced intent to acquire DCS, Higginson said, "The potential acquisition of this established automotive systems manufacturer could introduce significant revenue-generating capabilities while allowing us to optimize our drug delivery technology and advance commercial opportunities. Our intent is to acquire DCS without any additional equity capital by utilizing a new senior secured credit facility, once finalized, with a leading financial institution. We believe the combination of significant revenue from the automotive systems business and the potential high margin opportunities from both our drug and supplement product pipeline could strengthen earnings visibility, support a more capital-efficient growth model, and enhance long-term shareholder value."

Aspire Enters into Commitment Letter for Acquisition of DCS

The Company entered into a commitment letter with a national financial institution providing for a senior secured credit facility of Aspire in an aggregate principal amount of up $22,500,000 (the "Aspire Credit Facility"). Aspire intends to use the proceeds of the Aspire Credit Facility, if consummated, to finance the acquisition of 100% of DCS. The Company does not anticipate procuring any new equity raise to consummate the purchase.

The Aspire Credit Facility is expected to consist of a senior secured five-year term loan, at an interest rate equal to 325 basis points above the one-month term Secured Overnight Financing Rate. The final terms of the Aspire Credit Facility, including the senior secured term loan, will be subject to execution of definitive credit documentation and the satisfaction of customary closing conditions.

Offering Agent

RBW Capital Partners LLC, whose securities and brokerage services are offered through Dawson James Securities, Inc., acted as sole placement agent for the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. Additional risks specific to the proposed acquisition of DCS include, without limitation: the risk that the parties may fail to finalize a definitive acquisition agreement or that the proposed transaction may not be consummated on the terms or timeline currently contemplated, or at all; the risk that due diligence, including the audit of DCS's financial statements under U.S. GAAP, may reveal information that adversely affects the terms or viability of the transaction; risks related to DCS's business, including its dependence on key automotive OEM customers, exposure to cyclical conditions in the global automotive industry, potential liabilities associated with DCS's operations and intellectual property, the ability to successfully integrate DCS's operations following closing, consummation of the Aspire Credit Facility, and the risk that anticipated synergies and financial benefits from the acquisition may not be realized. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Aspire (ASBP) raise in the April 20, 2026 private placement?

Aspire raised $21.0 million in aggregate gross proceeds from the Series A preferred placement. According to the company, proceeds came from two tranches and are intended for working capital, part of the DCS cash purchase, and general corporate purposes.

What are the key terms of Aspire's committed credit facility to buy DCS?

Aspire has a commitment letter for up to $22.5 million in a senior secured five‑year term loan. According to the company, the loan would bear interest at one‑month SOFR plus 325 basis points and requires definitive credit documentation and customary closings.

What is Aspire paying for Dura Control Systems (DCS) in the April 2026 LOI?

Aspire intends to acquire 100% of DCS for a total purchase price of $30.0 million paid in cash. According to the company, DCS generated over $200M in revenue and about $20M adjusted EBITDA in FY2025 (unaudited).

Will Aspire need to raise new equity to complete the DCS acquisition (ASBP)?

Aspire does not expect to raise additional equity to consummate the DCS purchase. According to the company, the plan is to use the committed senior secured credit facility and existing proceeds from the private placement to fund the transaction.

How does the $21M financing affect Aspire's Nasdaq listing status?

The financing increased Aspire's stockholders' equity above the Nasdaq minimum of $2.5M. According to the company, this satisfies the listing threshold required to maintain its Nasdaq Capital Market listing.

How does the Aspire Credit Facility affect shareholders if finalized?

The credit facility would increase Aspire's leverage by up to $22.5M of senior secured debt. According to the company, debt financing avoids immediate equity dilution but will introduce interest expense and customary loan covenants if executed.